TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05167045

Intervention type: BEHAVIORAL
Intervention: Brain Health PRO
Description: The BHSP is an educational program designed to teach about dementia. It aims to provide best available evidence for lifestyle changes that can help lower dementia risk, and to provide specific recommendations for positive lifestyle changes (e.g., physical exercises to try at home, healthy recipes). The program was developed as a collaborative effort by Canadian investigators who have expertise in the different areas of dementia prevention, along with input from older-adult citizen advisors.
Study: NCT05508711

Intervention type: DEVICE
Intervention: FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device
Description: Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).

Intervention type: DEVICE
Intervention: FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device
Description: Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).
Study: NCT06401954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity focused electromagnetic therapy
Description: High-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is set to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Foot core training
Description: Foot core training will consist of 4 exercises with 10 repetitions per set and 3 sets per session for each exercise.~Twice a week for a total of six weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot core training
Description: Foot core training will consist of 4 exercises with 10 repetitions per set and 3 sets per session for each exercise.~Twice a week for a total of six weeks.
Study: NCT06099600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reconstructive surgery of the anterior cruciate ligament
Description: surgical reconstruction after rupture of the anterior cruciate ligament is widely proposed as first-line treatment, with the aim of restoring knee joint stability and facilitating functional recovery
Study: NCT05981339

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: breathing exercises
Description: For the diaphragmatic breathing exercise, patients are asked to perform a nasal inspiration and expiration that moves predominantly the abdomen by reducing the movement of the thorax in the semi-supine position. To give tactile stimulation, one hand of the patient is placed on the chest with the other hand on the abdominal region. Continue this exercise for three minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercises
Description: For the diaphragmatic breathing exercise, patients are asked to perform a nasal inspiration and expiration that moves predominantly the abdomen by reducing the movement of the thorax in the semi-supine position. To give tactile stimulation, one hand of the patient is placed on the chest with the other hand on the abdominal region. Continue this exercise for three minutes.
Study: NCT06099600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive surgery of the anterior cruciate ligament
Description: surgical reconstruction after rupture of the anterior cruciate ligament is widely proposed as first-line treatment, with the aim of restoring knee joint stability and facilitating functional recovery
Study: NCT04967599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phenotype Feedback Intervention
Description: Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phenotype Feedback Intervention
Description: Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genotype Feedback Intervention
Description: Online session providing personalized feedback on alcohol metabolism genotypes and associated health-related risks.
Study: NCT05132296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Undergo behavioral counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care supportive services

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Receive FitBit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Receive nutrition education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Undergo physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06099509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered oral glucose tolerance test
Description: Participants will be asked to self-administer the postpartum 75-gram oral glucose tolerance test. They will be provided the glucose solution and instructions. A 4 week virtual visit will be arranged where the test results will be reported to the provider and appropriate follow up arranged based on the results of their screen.
Study: NCT05410860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil NS 70 mg
Description: Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study: NCT06678347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership for recovery
Description: The intervention will be delivered as a group-based programme (6 sessions) to the managers of the included employees. The programme includes educative and reflective parts as well as various strategies promoting both managers' own recovery and the recovery of employees.
Study: NCT06675513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name:
Description: Autologous WD-01 CAR-T therapy with Wondercel's Warrior armor strategy will be explored for its advantage over other armor platforms.
Study: NCT06679114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The single-session ACT group intervention will involve a mixture of didactic instruction, discussion, metaphors, and experiential activities. ACT activities will help women notice and accept that negative thoughts, emotions, and experiences while being displaced by war are part of migratory and post-migratory life. ACT activities will also help them identify, reorient towards, and commit to values-consistent behaviors through effective goal-setting. The single-session will be approximately 3 hours long.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Usual care will be minimally enhanced by providing participants with an educational information session that provides information on health promotion.
Study: NCT06682481

Intervention type: OTHER
Intervention: Measurement of biomarker
Description: Measurement of blood levels of 1,5-anhydroglucitol
Study: NCT06682572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib (VS-6766) + Defactinib (VS-6063)
Description: combination therapy
Study: NCT06686147

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Joint Range of Motion
Description: Joint range of motion (ROM) measurements will be conducted to assess the specific ranges of motion of participants' joints.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Joint Range of Motion
Description: Joint range of motion (ROM) measurements will be conducted to assess the specific ranges of motion of participants' joints.
Study: NCT06692621

Intervention type: DRUG
Intervention: Oxytocin
Description: Medicines were administered in appropriate doses

Intervention type: DRUG
Intervention: Carbetocin
Description: Medicines were administered in appropriate doses
Study: NCT06689540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTS105
Description: MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg.
Study: NCT06401954

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Foot core training
Description: Foot core training will consist of 4 exercises with 10 repetitions per set and 3 sets per session for each exercise.~Twice a week for a total of six weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham high-intensity focused electromagnetic therapy
Description: Sham high-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is unable to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks
Study: NCT05389670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta-burst stimulation (cTBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Continuous Theta-burst stimulation (cTBS)
Description: Sham cTBS, inhibitory-like patterned form of TMS.
Study: NCT05981339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manual therapy techniques
Description: * Sacral release: While the patient is in the side lying position, the physiotherapist goes behind the patient, one hand is placed on the lower abdominal area, and the thenar and hypothenar areas of the other hand are placed on the basis of the sacrum. It is waited until a general relaxation is felt in the tissue under the hands (Stone, C., 2006).~* Bladder mobilization: Two hands are placed just above the pubic region and gently pressed down first to test the surface protrusion of the uterus. During the application, the pressure of the hand is adjusted according to the tension of the tissue. Hand contact is not interrupted until the fascial tissue under the hand is relaxed (Stone, C., 2006).
Study: NCT06395129

Intervention type: DEVICE
Intervention: Low dead-space syringes/needles
Description: LDSS/N are a type of syringe/needle which retains less residual blood following an injecting event when compared to HDSS/N.

Intervention type: DEVICE
Intervention: Hepatitis C Antibody Rapid Diagnostic Test
Description: Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months

Intervention type: DEVICE
Intervention: HIV rapid Diagnostic Test
Description: Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
Study: NCT05115669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wortie freeze plus
Description: treatment of common and plantar warts
Study: NCT04716465

Intervention type: OTHER
Intervention: Dysautonomia
Description: Indicators of dysautonomia
Study: NCT06689540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTS105
Description: MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTS105
Description: MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTS105
Description: MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTS105
Description: MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg.
Study: NCT06681207

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a-tDCS)
Description: Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Stroke participants in the first two groups will receive five sessions of the assigned brain stimulation combined with visuomotor stepping training over five consecutive days. Healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a-tDCS)
Description: Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Stroke participants in the first two groups will receive five sessions of the assigned brain stimulation combined with visuomotor stepping training over five consecutive days. Healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.
Study: NCT05396417

Intervention type: PROCEDURE
Intervention: cesarean delivery
Description: Cesarean delivery under any form of anesthesia for any reason and for any indication
Study: NCT06693115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM with alerts
Description: CGM devices will be set to alert the care team when interstitial glucose levels hit 250 mg/dL and 150 mg/dL. Dexcom 7s automatically alert when glucose levels are 55 mg/dL or lower. Nurses will be instructed to check the glucose trends on the CGM device when alerted. They will be asked to check glucose levels with a FSBG according to the following instructions:~1. CGM alerts to interstitial glucose level of 250 mg/dL AND trend indicates rapidly decreasing glucose levels (indicated by double down arrow on Dexcom 7)~2. CGM alerts to interstitial glucose level of 150 mg/dL or less.
Study: NCT06253650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 6 cycles of: T-DXd at the dose of 6.4 mg/kg intravenous every 3 weeks plus capecitabine 1000 mg/sqm BID orally on days 1-14 every 3 weeks or 5-fluorouracil 600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks as per Investigator's choice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 4 cycles of: 5-fluorouracil 2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks, leucovorin 200 mg/m2 intravenous infusion on day 1 every 2 weeks, oxaliplatin 85 mg/m2 intravenous infusion on day 1 every 2 weeks, and docetaxel 50 mg/m2 intravenous infusion on day 1 every 2 weeks.
Study: NCT06693791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim N01
Description: Romiplostim N01 was administered subcutaneously once weekly from +1 day to +28 days after UCBT at a recommended starting dose of 5µg/Kg (maximum single dose not to exceed 250µg) for a total of 4 administrations, with the option of continuation of dosing/switching/discontinuing after +28 days, depending on the patient's platelet profile.
Study: NCT06693245

Intervention type: PROCEDURE
Intervention: VAS scores of the puncture
Description: All patients were evaluated by our team with CEAP grading and ultrasound measurements to record the diameter of the saphenous vein before surgery。We performed endovenous microwave ablation of the great saphenous vein along with foam sclerotherapy and point stripping treatment. We documented the operating room temperature, puncture site, VAS scores during puncture and catheter placement, the amount of injected tumescent fluid, radiofrequency generator used, and data at the conclusion of the surgery. A descriptive analysis of intraoperative pain scores was conducted to evaluate the level of pain experienced during the surgery. A nonparametric test was utilized to analyze the relationship between preoperative and intraoperative factors and the level of pain experienced during the surgery.
Study: NCT06691906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide decanoate
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide decanoate
Description: Oral tablet
Study: NCT06715436

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mediterranean Diet
Description: The MedDiet will be planned according to the Mediterranean diet pyramid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Modified Atkins diet with a maximum of 20 g of carbohydrates per day.
Study: NCT06475807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fermented food
Description: Step 1: patients will consume high-fermented food

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber supplementation
Description: Step 2: High fiber supplementation
Study: NCT06377020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT2
Description: Behavioral lifestyle intervention
Study: NCT06715436

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control group
Description: The control group will be asked to continue their dietary and lifestyle habits
Study: NCT06717425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Taken once daily
Study: NCT06230874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME Protocol
Description: The HOME Protocol is a newly developed nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Five components of the HOME Protocol include Reflect (1 minute of self-reflection and self-talk), Reset (2 minutes for breathing with stillness/silence and body check), Reach (3 minutes for stretching and progressive muscular relaxation), Renew (2 minutes for breathing with meditation/gratitude), and Re-engage (1 minute for self-reflection and self-talk).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Journaling Protocol
Description: The control journaling protocol is a nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness self-talk and journaling strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Three components of the control journaling protocol include Reflect (1 minute of self-reflection and self-talk), Write (journaling), and Re-engage (1 minute for self-reflection and self-talk).
Study: NCT05982600

Intervention type: DIAGNOSTIC_TEST
Intervention: Single Assessor Teledermatological triage (TDT)
Description: The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.

Intervention type: DIAGNOSTIC_TEST
Intervention: 2 people Teledermatological triage (TDT)
Description: The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
Study: NCT06717425

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken once daily
Study: NCT06716879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donzakimig
Description: Drug: Donzakimig Pharmaceutical form: Subcutaneous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donzakimig
Description: Drug: Donzakimig Pharmaceutical form: Subcutaneous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donzakimig
Description: Drug: Donzakimig Pharmaceutical form: Subcutaneous solution